Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48 plus tislelizumab as neoadjuvant therapy in HER2-positive muscle-invasive bladder cancer
ChiCTR2200060153Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and tislelizumab in transitional cell carcinoma of the bladder (TCC) and bladder cancer, sponsored by West China Hospital of Sichuan University. Primary endpoints: Clinical complete response rate and Pathologic complete response rate. Planned start May 2022; status: not yet recruiting.
02
Drugs
disitamab vedotintislelizumab
03
Conditions
transitional cell carcinoma of the bladder (TCC)bladder cancer
Beyond the preview
Go deeper on ChiCTR2200060153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060153.